Neuromersiv Pty Ltd

Neuromersiv occupies a specialized position at the intersection of digital health, rehabilitation hardware, software, and immersive computing. Its differentiation is the combination of a controller-free Meta Quest 2 therapy system, task-specific upper-limb exercises, clinician monitoring, and real-time viewing of patient sessions. The focus on stroke, spinal cord injury, and acquired brain injury creates a narrower clinical use case than general wellness or consumer virtual-reality products. Ulysses is also described as Australian TGA- and UK MHRA-approved, which may support use in regulated care environments, while NDIS, workers compensation, and home-care eligibility addresses Australian funding pathways. Its category footprint spans Electronics, Health Care, and Software, but the company’s small recorded team of fewer than ten employees and cumulative funding of USD 1.11 million indicate a focused early-stage operating model rather than a scaled platform business. The closed operating-status flag further limits confidence in its current competitive activity.

Neuromersiv’s financing history shows an early-stage progression from a USD 58,493 convertible note in January 2018 and a USD 19,301 grant in April 2018 to a USD 35,970 convertible note in September 2018. The company then raised USD 132,638 in a pre-seed round in August 2019, followed by grants of USD 152,581 in February 2020 and USD 682,222 in June 2020. In total, the profile records USD 1,114,260 across eight rounds, with grants representing the largest disclosed component. Product development progressed toward a connected rehabilitation system comprising Ulysses hardware, clinician software, real-time streaming, and telehealth support. Leadership continuity is visible through Anshul Dayal’s CEO role from 2018 and Oliver Morton-Evans’s COO role from 2018, while the recorded team remains below ten employees. The trajectory therefore reflects technical and regulatory development supported by grants, but not clear evidence of commercial scale. The closed operating-status designation is the strongest counter-signal to continued growth.